Literature DB >> 21251458

Pathophysiology and therapeutic options in primary immune thrombocytopenia.

Roberto Stasi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21251458      PMCID： PMC3136592          DOI： 10.2450/2010.0080-10

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  102 in total

1.  Use of recombinant factor VIIa in a thrombocytopenic patient with spontaneous intracerebral haemorrhage.

Authors:  Stefano Busani; Marco Marietta; Alberto Pasetto; Massimo Girardis
Journal:  Thromb Haemost       Date:  2005-02       Impact factor: 5.249

2.  Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura.

Authors:  Ann Reed Gaines
Journal:  Blood       Date:  2005-05-05       Impact factor: 22.113

Review 3.  How I treat idiopathic thrombocytopenic purpura (ITP).

Authors:  Douglas B Cines; James B Bussel
Journal:  Blood       Date:  2005-06-07       Impact factor: 22.113

Review 4.  Management of patients with refractory immune thrombocytopenic purpura.

Authors:  J N George
Journal:  J Thromb Haemost       Date:  2006-08       Impact factor: 5.824

Review 5.  Fcgamma receptors: old friends and new family members.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Immunity       Date:  2006-01       Impact factor: 31.745

6.  Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization.

Authors:  Bipin N Savani; Cynthia E Dunbar; Margaret E Rick
Journal:  Am J Hematol       Date:  2006-03       Impact factor: 10.047

Review 7.  Treatment of immune thrombocytopenic purpura in adults.

Authors:  James Bussel
Journal:  Semin Hematol       Date:  2006-07       Impact factor: 3.851

8.  Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia.

Authors:  Zongdong Li; Michael A Nardi; Simon Karpatkin
Journal:  Blood       Date:  2005-03-17       Impact factor: 22.113

9.  Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist.

Authors:  Connie L Erickson-Miller; Evelyne DeLorme; Shin-Shay Tian; Christopher B Hopson; Kenneth Stark; Leslie Giampa; Elizabeth I Valoret; Kevin J Duffy; Juan L Luengo; Jon Rosen; Stephen G Miller; Susan B Dillon; Peter Lamb
Journal:  Exp Hematol       Date:  2005-01       Impact factor: 3.084

10.  Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies.

Authors:  Michelle Lee Webster; Ebrahim Sayeh; Min Crow; Pingguo Chen; Bernhard Nieswandt; John Freedman; Heyu Ni
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113
View more
  12 in total

1.  Pulsed high-dose dexamethasone improves interleukin 10 secretion by CD5+ B cells in patients with primary immune thrombocytopenia.

Authors:  Fanli Hua; Lili Ji; Yanxia Zhan; Feng Li; Shanhua Zou; Xiaoyun Wang; Dongli Song; Zhihui Min; Song Gao; Yangjiong Wu; Hao Chen; Yunfeng Cheng
Journal:  J Clin Immunol       Date:  2012-06-06       Impact factor: 8.317

Review 2.  Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom?

Authors:  J E Vaughn; F Anwer; H J Deeg
Journal:  Vox Sang       Date:  2015-07-14       Impact factor: 2.144

3.  In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor.

Authors:  Boris Shenkman; Yulia Einav; Tami Livnat; Ivan Budnik; Uriel Martinowitz
Journal:  Blood Transfus       Date:  2013-11-29       Impact factor: 3.443

Review 4.  Pathophysiology and management of primary immune thrombocytopenia.

Authors:  Hirokazu Kashiwagi; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2013-05-24       Impact factor: 2.490

5.  Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach.

Authors:  Maria L Lozano; Cristina Segú-Vergés; Mireia Coma; María T Álvarez-Roman; José R González-Porras; Laura Gutiérrez; David Valcárcel; Nora Butta
Journal:  Int J Mol Sci       Date:  2021-06-27       Impact factor: 5.923

6.  Changes in follicular helper T cells in idiopathic thrombocytopenic purpura patients.

Authors:  Jue Xie; Dawei Cui; Yan Liu; Jie Jin; Hongyan Tong; Lei Wang; Guoxiang Ruan; Yun Lu; Huiming Yuan
Journal:  Int J Biol Sci       Date:  2015-01-05       Impact factor: 6.580

7.  Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag.

Authors:  Michael D Tarantino; Kalpana K Bakshi; Andrés Brainsky
Journal:  Platelets       Date:  2013-02-12       Impact factor: 3.862

Review 8.  Advances in Diagnosis and Treatments for Immune Thrombocytopenia.

Authors:  Shosaku Nomura
Journal:  Clin Med Insights Blood Disord       Date:  2016-07-17

9.  Human platelet antigens and primary immune thrombocytopenia.

Authors:  Vagner Castro
Journal:  Rev Bras Hematol Hemoter       Date:  2017-03-11

10.  Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia.

Authors:  Francesco Rodeghiero; Dariusz Woszczyk; Borhane Slama; Anait Melikyan; Jean-Francois Viallard; Rabye Ouaja; Ousmane Alfa Cisse; Alain Sadoun; Abdulgabar Salama
Journal:  J Hematol       Date:  2018-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.